Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefpodoxime. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 6/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.87 |
| ▸ | PPARG | P37231 | 2/20 | 0.87 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.87 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.87 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.87 |
| ▸ | ALB | P02768 | 1/20 | 0.87 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.74 |
| ▸ | APEX1 | P27695 | 3/20 | 0.74 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefpodoxime SCHEMBL69122 | 1.00 | NR1I2 (1.00) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefpodoxime SCHEMBL2015784 | 1.00 | NR1I2 (1.00) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefpodoxime SCHEMBL16072818 | 1.00 | NR1I2 (1.00) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefpodoxime SCHEMBL6688590 | 1.00 | NR1I2 (1.00) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefpodoxime SCHEMBL13189562 | 1.00 | NR1I2 (1.00) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefpodoxime SCHEMBL27072 | 1.00 | NR1I2 (1.00) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefpodoxime SCHEMBL3014534 | 0.99 | NR1I2 (0.98) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefpodoxime SCHEMBL8868198 | 0.99 | NR1I2 (0.98) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefpodoxime SCHEMBL6238484 | 0.99 | NR1I2 (0.98) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefpodoxime SCHEMBL5265715 | 0.99 | NR1I2 (0.98) | NR1I2HTR2CMAPTPPARGSLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0029557-A2 | 7-Acylamino-3-substituted cephalosporanic acid derivatives, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-03 | — | — | EP | claimed |
| JP-60185787-A | — | — | None | — | — | JP | disclosed |
| WO-2011077217-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID | NECTAR LIFESCIENCES LTD. (IN) | 2011-06-30 | — | — | WO | disclosed |
| EP-1389187-A4 | PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID | RANBAXY LAB LTD (IN) | 2005-03-16 | — | — | EP | disclosed |
| US-20050020561-A1 | Process for the preparation of cefpodoxime acid | RANBAXY LABORATORIES LIMITED (IN) | 2005-01-27 | — | — | US | disclosed |
| WO-2004083216-A1 | A PROCESS FOR THE PREPARATION OF CEPHALOSPORINS | ORCHID CHEMICALS & PHARMACEUTICALS LTD (IN) | 2004-09-30 | — | — | WO | disclosed |
| US-20040132995-A1 | Process for the preparation of cephalosporins | ORCHID CHEMICALS & PHARMACEUTICALS, LTD. (IN) | 2004-07-08 | — | — | US | disclosed |
| EP-1389187-A2 | PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID | Ranbaxy Laboratories Limited (IN) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002083634-A2 | PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID | RANBAXY LABORATORIES LIMITED (IN) | 2002-10-24 | — | — | WO | disclosed |
| EP-1178992-A2 | PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID | Ranbaxy Laboratories, Limited (IN) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000068234-A2 | PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID | RANBAXY LABORATORIES LIMITED (IN) | 2000-11-16 | — | — | WO | disclosed |
| US-4716158-A | CEPHALOSPORINS SUITABLE FOR ORAL ADMINISTRATION | SANKYO COMPANY LIMITED (JP) | 1987-12-29 | — | — | US | disclosed |
| JP-S60185787-A | 7-ACYLAMINO-3-SUBSTITUTED-CEPHALOSPORANIC ACID DERIVATIVE AND PREPARATION THEREOF | FUJISAWA PHARMACEUT CO LTD | 1985-09-21 | — | — | JP | disclosed |
| US-4486425-A | ANTIBIOTICS | SANKYO COMPANY LIMITED (JP) | 1984-12-04 | — | — | US | disclosed |
| EP-0049118-A2 | Cephalosporin derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1982-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020561-A1 | Process for the preparation of cefpodoxime acid | CYP2F1, CYP4F11, CYP51A1 | NR1I2 2108/4885HTR2C 3939/4885MAPT 3974/4885 |
| US-20040132995-A1 | Process for the preparation of cephalosporins | CYP2F1, CYP7A1, MRPL21 | NR1I2 880/4885HTR2C 4411/4885MAPT 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.